When: Price approaches $1,018 (June support/Bollinger lower)

Then: Exit remaining position

Trim 15-20% of position (not 40%); Buy three-month protective puts with strike around $1,040 expiring after Q3 print; Set hard stop at $1,048 (above 200 SMA); Cap position at 50% of pre-event weight through earnings; Defined reload plan if 200 SMA holds on closing basis or BLK reports clean Q3 print.

• BLK trailing twelve month free cash flow of $7.58 billion
• Forward P/E of 16.69
• PEG ratio below 1
• 200 SMA tested at approximately $1,050 on September 16th; stock printed low of $1,037.24, closed back above 200 SMA
• Currently trading at $1,073, which is 2.2% above the 200 SMA
• iShares franchise operates as oligopoly with Vanguard and State Street
• Aladdin is industry standard risk platform used by other asset managers
• First on-chain tokenized model portfolios launched with Ondo
• Deploying $25 billion into Asia AI data centers
• Normalized EBITDA grew 34% year-over-year last quarter
• 200 SMA support held on closing basis; not a failed support test
• Quality franchises mean revert rather than breakdown to technical levels
• Hedging with puts is more appropriate capital-efficient response than trimming equity
• Sitting in cash with hawkish Fed and negative real yields destroys purchasing power

→ vs aggressive: Trim size of 25-40% is too large for a quality franchise like BLK; treating BLK like a momentum biotech with no earnings power when it has $7.58B FCF, P/E of 16.69, and PEG below 1 is a critical error in framing

→ vs aggressive: Loose language on 200 SMA 'violation'—the $1,050 level was tested intraday with $1,037.24 low but closed back above; this is textbook support hold, not a failed support test; the position change is being driven by imprecise technical analysis

→ vs aggressive: Asymmetry argument mispriced; basing 1.8:1 downside/upside on technicals ignores BLK's business quality including iShares oligopoly, Aladdin platform, tokenization launch, and 34% EBITDA growth; floor is significantly higher than Bollinger Band at $1,016

→ vs aggressive: The statement that 'long-term quality does NOT protect you from near-term air pocket' is true but incomplete; quality affects how much air pocket you're willing to tolerate, and appropriate response to near-term risk with accelerating earnings is hedging, not sizing down

→ vs neutral: Staying sidelined in cash with negative real yields means losing purchasing power daily; opportunity cost is explicitly negative with hawkish Fed and inverted yield curve

SELL rating with 20-25% trim, collar strategy (sell call at ~$1,140, buy put at ~$1,030), closing-basis stop loss at $1,035-$1,040, and three explicit reload triggers

• SELL call directionally correct with trim magnitude between aggressive (40%) and conservative (15%) at 20-25%
• 200 SMA successfully defended: closed above support, currently trading 2.16% above with long lower wick = bullish reversal signal
• Fundamentals remain compelling: 30.6% YoY revenue growth, 34% normalized EBITDA growth, $7.58B TTM free cash flow, forward P/E 16.69, PEG 0.89
• Already corrected 11.9% from August 13 peak ($1,176.80) to September 16 low ($1,037.24)
• Collar strategy preferred over protective puts due to elevated IV making puts expensive (3-5% position cost)
• Stop at $1,035-$1,040 based on closing basis only to avoid intraday liquidity sweeps
• Three reload triggers: (1) Close above 50 SMA ($1,104) with above-average volume reloads 50%, (2) Clean Q3 earnings reloads remaining 50%, (3) Close below $1,035 on volume triggers full exit
• Rising yields are also tailwind for bond ETF flows: 80% of global bond market now yields above 4% per BlackRock research
• Social sentiment mildly bullish at 6.2/10 with medium confidence, not at bearish extreme needed for aggressive trim
• Ondo tokenization is first-ever onchain deployment of BlackRock model portfolios; Deutsche Bank forecasts $3-4T tokenized assets by 2035; $25B Asia AI data center bet signals continued growth posture

→ vs aggressive: Magnitude overshoot: 25-40% trim treats BLK like a momentum biotech with no earnings power, not a compounder with 30.6% revenue growth and $7.58B FCF

→ vs aggressive: 200 SMA was NOT violated: price closed above support at $1,037.24, currently 2.16% above—the 'failure' didn't hold

→ vs aggressive: Downside already priced in: 11.9% correction from peak already occurred, arguing against panic-selling at the bottom of the move

→ vs aggressive: Social sentiment at 6.2/10 is mildly bullish, not bearish extreme needed to justify 40% trim

→ vs conservative: Protective puts too expensive: elevated IV environment makes 3-month puts cost 3-5% of position value with questionable coverage

→ vs conservative: Trim too small: 15% barely reduces risk in elevated volatility environment with ATR of $24.91 (2.3% of price)

→ vs conservative: Stop at $1,048 is only ~$25 from current price (~1 ATR), setting up for whipsaw in hawkish macro regime

→ vs conservative: Intellectually inconsistent: uses quality to justify less hedging but doesn't quantify acceptable drawdown threshold